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Abstract
Background: Aberrant CpG island promoter DNA hypermethylation is frequently observed in cancer and is
believed to contribute to tumor progression by silencing the expression of tumor suppressor genes. Previously, we
observed that promoter hypermethylation in breast cancer reflects cell lineage rather than tumor progression and
occurs at genes that are already repressed in a lineage-specific manner. To investigate the generality of our
observation we analyzed the methylation profiles of 1,154 cancers from 7 different tissue types.
Results: We find that 1,009 genes are prone to hypermethylation in these 7 types of cancer. Nearly half of these
genes varied in their susceptibility to hypermethylation between different cancer types. We show that the
expression status of hypermethylation prone genes in the originator tissue determines their propensity to become
hypermethylated in cancer; specifically, genes that are normally repressed in a tissue are prone to
hypermethylation in cancers derived from that tissue. We also show that the promoter regions of
hypermethylation-prone genes are depleted of repetitive elements and that DNA sequence around the same
promoters is evolutionarily conserved. We propose that these two characteristics reflect tissue-specific gene
promoter architecture regulating the expression of these hypermethylation prone genes in normal tissues.
Conclusions: As aberrantly hypermethylated genes are already repressed in pre-cancerous tissue, we suggest that
their hypermethylation does not directly contribute to cancer development via silencing. Instead aberrant
hypermethylation reflects developmental history and the perturbation of epigenetic mechanisms maintaining these
repressed promoters in a hypomethylated state in normal cells.
Background
Aberrant DNA hypermethylation of CpG island (CGI)
promoters (promoter hypermethylation) occurs in many
cancers. This epigenetic reprogramming is associated
with the absence of transcription and can occur at a
number of known tumor suppressor genes, suggesting
that it contributes to tumor progression by silencing the
expression of affected genes [1]. Although this model has
been hugely influential, the significance of hypermethyla-
tion at CGIs in cancer has long been debated and ques-
tioned [2-4]. Also, despite intense study, the mechanisms
directing promoter hypermethylation in cancer remain
elusive and it is unclear whether the same mechanism
operates in different cancer types. In colorectal cancer, a
CGI hypermethylator phenotype (termed CIMP) has
been described where hundreds of CGIs become coordi-
nately hypermethylated during tumor progression [5,6].
Similar methylator phenotypes have been reported to
occur in cancers originating from other tissues [7-9]. In
these cases, it is particularly unclear whether hyper-
methylation is the primary event responsible for the
silencing of target genes, however based on the propen-
sity of large numbers of genes to become re-activated by
exposure to DNA de-methylating drugs, it has been sug-
gested that this might be the case [10].
Hypermethylation also plays a role in the regulation of
some genes during normal development, particularly at
imprinted loci and at CGI promoters on the inactive
X-chromosome (Xi) in female mammalian cells [11,12].
During X-inactivation CGI hypermethylation occurs
after gene silencing has already taken place [13,14] and
the initial silencing event does not require DNA
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methyltransferases [15,16]. Absence of the maintenance
methyltransferase, Dnmt1, in mice can lead to reactiva-
tion of the Xi later in development suggesting that in
this case CGI hypermethylation acts as a stabilizing fac-
tor that maintains silencing [15]. Where the temporal
dynamics of gene inactivation have been studied for
autosomal genes, hypermethylation occurs subsequent
to repression by other mechanisms [17].
We have recently shown that genes whose promoters
are hypermethylated in breast cancer cell lines and tumors
are already repressed in the putative lineage of origin and
that when methylation is removed in cancer cell lines,
either pharmacologically or genetically, most hypermethy-
lated genes do not become re-activated [18]. This implies
that the majority of cancer-associated CGI hypermethyla-
tion does not contribute to tumor progression under the
classic model because it occurs at genes that are already
switched off. Others have shown that hypermethylation of
APC frequently occurs in gastric cancer, but at a promoter
that is not utilized in normal gastric tissue [19] and that
RUNX3, whose tumor suppressor gene status is largely
based on the fact that it is frequently methylated in gastric
cancer, is never expressed in the gastrointestinal epithelial
cells that give rise to these tumors [20].
Here, we explore the generality of our observations in
breast cancer by analyzing data derived from 1,154 tumors
arising in 7 different human tissues. We show that varia-
bility in promoter CGI hypermethylation patterns between
tumors is explained by variability in gene expression pat-
terns between normal tissues and it is genes that are
repressed in the pre-cancerous tissue that become prefer-
entially hypermethylated in tumors. Our study represents
the first comprehensive analysis of promoter CGI hyper-
methylation in different human cancers and we propose
that the hypermethylation of repressed CGI promoters is a
common feature of most cancers.
Results
Tissue of origin determines promoter hypermethylation
patterns in cancers
We have previously shown that cell lineage determines
promoter hypermethylation patterns in breast cancer [18].
To examine the generality of these observations in cancers
arising in other tissues, we collected methylation profiling
data from 1,149 tumors of 7 different cancer types: breast
(Gene Expression Omnibus, [21], GEO:GSE31979), color-
ectal (GEO:GSE25062), prostate (GEO:GSE26126), lung
(The Cancer Genome Atlas, TCGA[22]) and ovarian
tumors (TCGA), along with acute-myeloid leukemias
(AMLs, TCGA) and glioblastomas (TCGA) [5,8,23-25].
These datasets were all generated using Illumina Infinium
HumanMethylation27 BeadChip methylation arrays, facili-
tating their cross comparison. We used these data to
define sets of genes that were frequently aberrantly
hypermethylated in each of the seven cancer types (See
Additional file 1, unmethylated in the corresponding nor-
mal tissue and methylated in >20% of cancer samples, see
methods for details). Our analyses were limited to genes
possessing CGI promoters because the hypermethylation
of non-CGI promoters is not always associated with tran-
scriptional repression [26,27]. The number of frequently
hypermethylated genes varied between cancer types with
the greatest number found in colorectal and lung tumors
(382 and 396 genes, respectively) and the least found in
ovarian tumors (100 genes) (See Additional file 2, Figure
S1A). To assess the reproducibility of these lists, we
derived a second set of genes frequently aberrantly hyper-
methylated in breast tumors from a meta-analysis of three
studies [7,18,28]. Of these 316 genes, 81.5% (256) were
found in our original list, a highly significant overlap (P <
2 × 10-16, Fisher’s exact test), demonstrating the reprodu-
cibility of our methodology. In total, 1,009 genes were
prone to hypermethylation by this analysis in at least one
type of cancer, including a number reported to be fre-
quently hypermethylated in cancer (for example, APC,
DAPK1, ESR1, GSTP1, SFRP genes and HOX genes)
[29-31]. None of the 1,009 gene sets were common to all
cancer types and roughly half (503 genes) were unique to
a single cancer type.
The overall levels of DNA methylation at these 1,009
hypermethylation-prone genes varied dramatically within
cancer types but were highest in colorectal tumors and
lowest in ovarian tumors (Figure 1a and Additional file 2
Figure S1B). Examination of the methylation profiles of
the 1,009 genes in the different cancer samples revealed
that 220 of the genes were consistently methylated in can-
cers of different tissues (in at least 5% of samples for each
tissue, Figure 1a). However, 446 of the genes had variable
methylation profiles and were hypermethylated in some
cancer types but not in others (Figure 1a, tick marks). For
example, 86 of the 1,009 hypermethylation prone genes
were never methylated in breast tumors but were methy-
lated in at least one other cancer type. To systematically
analyze sources of variation in the methylation profiles of
the 1,149 samples, we performed principal component
analysis (PCA) on the methylation data for the set of 1,009
hypermethylation prone genes [32]. The first principal
component accounted for around 66% of the variance in
the data and was significantly correlated with the median
methylation level of the 1,009 hypermethylation prone
genes (Figure 1b, R = 0.90, P < 2 × 10-16). The next three
components of the data accounted for 10.4% of the var-
iance in the data and clearly separated out the samples
into the seven different tissue types (Figure 1c). These ana-
lyses indicate that a substantial number of genes are prone
to hypermethylation in multiple cancer types but that the
susceptibility of many other genes to hypermethylation in
cancer is determined by tissue-type specific factors.
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Genes prone to hypermethylation in cancer are not
constitutively expressed
Having defined genes that were prone to hypermethyla-
tion in cancer, we next examined which factors affected
their propensity to become hypermethylated. As a con-
trol, we derived a second set of genes that were resistant
to hypermethylation in cancer (those that were never
methylated in any of the 1,149 cancer samples tested;
2,123 genes). The hypermethylation-prone and -resistant
gene sets were associated with different Gene Ontology
(GO) terms (Figure 2a). In particular, resistant genes
were enriched in housekeeping terms such as ‘Mitotic
Figure 1 Tissue of origin determines promoter hypermethylation patterns in cancers. (a) Cancer type determines tumor methylation
profiles. Shown are heatmaps of methylation levels at the 1,009 hypermethylation prone genes in 7 tumor types. Genes are ordered by their
frequency of methylation in breast cancer and tumors by the number of methylated genes. The black tick marks adjacent to the heatmaps
indicate genes that are never methylated in that tumor type. (b) Most variation between tumors corresponds to levels of methylation at
hypermethylation prone genes. Shown is a scatter plot of the median methylation level at the 1,009 methylation prone genes in each of the
1,149 tumors against its value along the first principal component. Tumors are colored by type. The two values are significantly correlated (R =
-0.90, P < 2 × 10-16). (c) Tumor type specific components exist in tumor hypermethylation patterns. Shown is a three-dimensional scatter plot of
the values of each of the 1,149 tumors along the 2nd, 3rd and 4th principal components. Tumors are colored by type (as in (b)).
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Cell Cycle’, and ‘RNA Processing and Macromolecule
Catabolic Process’ whereas prone genes were enriched
in developmental terms such as ‘System Development’
and ‘Organ Development’. We have previously shown
that genes hypermethylated in breast cancer cell lines
are expressed in a tissue-specific fashion in normal tis-
sues and these functional terms might suggest that
genes hypermethylated in diverse primary cancers also
have tissue-specific expression patterns [18].
We used a method based on information theory to
directly quantify the degree of tissue-specificity in a given
gene’s expression pattern across nine normal tissues that
were profiled by high-throughput mRNA sequencing
(RNA-seq, Sequence Read Archive, SRA:SRA008403)
[33-35], with a higher score equating to a more tissue-spe-
cific pattern of expression. Hypermethylation prone genes
were significantly more tissue-specific than hypermethyla-
tion resistant genes (Figure 2b). We observed similar
results when we defined the specificity of expression from
a panel of 36 tissues profiled on microarrays (See Addi-
tional file 2, Figure S2A, GEO:GSE2361) [36] or varied the
thresholds used to define hypermethylation prone genes
(See Additional file 2, Figure S2B). Furthermore, genes fre-
quently hypermethylated in each of the seven different
cancers were also found to have tissue-specific expression
patterns (See Additional file 2, Figure S2C) as were genes
found to be hypermethylated in colorectal tumors by alter-
native methylation profiling techniques (methyl-binding
domain pull-down and sequencing, MBD-seq, or whole
genome bisulfite sequencing [37-39], Additional file 2,
Figure S2D, SRA:SRA029584 and [40,41]). Therefore,
genes prone to hypermethylation in cancer are robustly
associated with tissue-specific expression patterns in nor-
mal tissues. One possibility is that hypermethylation selec-
tively accumulates at tissue specific genes because the
disruption of many housekeeping genes might be cell-
lethal. However, we found that a set of CGI promoter
genes reported as recurrently mutated in breast tumors
showed no preference towards either tissue specific or
housekeeping expression patterns in normal tissues imply-
ing that the disruption of housekeeping genes is not neces-
sarily lethal, at least to breast tumor cells (See Additional
file 2, Figure S2E). Our analyses show that genes that are
prone to hypermethylation in cancer are distinguished
from those resistant to hypermethylation by their regu-
lated expression pattern in normal tissues.
Aberrantly hypermethylated genes have conserved
promoter regions
Based on genes hypermethylated in multiple cancer cell
lines, one study has suggested that the transcriptional start
sites (TSSs) of genes prone to hypermethylation are
depleted of repetitive elements [42]. We investigated
whether this was also true of our set of hypermethylation
prone genes derived from primary cancers. In our ana-
lyses, all three major classes of repetitive elements (LINEs,
SINEs and long terminal repeats (LTRs)) were depleted
from the TSSs of CGI promoters and to a lesser extent
non-CGI promoters (See Additional file 2, Figure S3A).
However, genes prone to hypermethylation in cancer had
a significantly greater depletion of repetitive elements than
hypermethylation resistant genes (Figure 3a). The greater
depletion from the promoters of hypermethylation prone
genes could be caused by an unknown activity of repetitive
Figure 2 Genes prone to hypermethylation in cancer are not constitutively expressed. (a) Hypermethylation-prone and -resistant genes
are associated with distinct biological processes. Shown are graphs of the percent enrichment or depletion for the 10 most enriched GO
biological process in the hypermethylation resistant and prone gene sets. For each term the enrichment or depletion in both gene sets is
plotted. All terms were enriched or depleted to a significant level for both gene sets (Fisher’s exact tests, P < 0.05). (b) Hypermethylation prone
genes are tissue-specific. Histograms show the distribution of tissue-specificity scores observed for hypermethylation prone and resistant genes.
Specificity scores for prone and resistant gene sets were compared using a Wilcoxon rank sum test. (*** P < 0.001). GO, genome ontology.
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elements in protecting CGIs from aberrant hypermethyla-
tion as has been previously suggested [42]. However, this
model is inconsistent with both the hypermethylation of
repetitive elements in normal tissues and their hypo-
methylation in cancer [43]. Based on our observation that
hypermethylation prone genes have tissue-specific expres-
sion patterns (Figure 2b), we considered an alternative sce-
nario. The expression pattern of tissue-specific genes is
often regulated by elements that lie distant to their promo-
ter [44]. The insertion of a transposable element close to a
tissue-specific gene might be detrimental to its regulation
because it could directly disrupt one of these regulatory
elements or interrupt their interaction with the gene pro-
moter. The depletion of repetitive elements seen at hyper-
methylation prone genes could, therefore, reflect an
evolutionary need to preserve the proper developmental
regulation of these genes.
Many of the bioinformatic techniques used to discover
functional elements in the human genome use compari-
sons of the genomes of multiple species to infer their
presence through evolutionary conservation [45]. There-
fore, a testable consequence of our hypothesis regarding
the presence of regulatory elements in the vicinity of
hypermethylation prone promoters is that we should
detect a greater degree of evolutionary constraint or
conservation around these promoters. We quantified the
level of evolutionary conservation around transcription
start sites using two different measures: one based on
the rate of nucleotide substitutions between species [46]
and the other based on the measurement of the rate of
insertions and deletions between species [47]. The pro-
files of these scores mirrored that of repetitive elements
and the greatest conservation was seen directly over the
TSS (Figure 3b). Conservation was greater downstream
of the TSS relative to the upstream region, probably due
to the presence of exonic sequences. However, hyper-
methylation-prone genes had significantly higher levels
of conservation as measured by both scores, at the TSS
and extending into the upstream and downstream
regions (Figure 3b). Similar results were observed for
Figure 3 Hypermethylated genes have conserved promoter regions. (a) Hypermethylation prone promoters are depleted of repetitive
elements. Shown are graphs of the frequency of LINEs, SINEs and LTRs at 1 kb intervals around hypermethylation prone and resistant TSSs. The
significance of the differences in densities observed at prone and resistant genes were determined using Fisher’s exact tests for the repeat
counts ± 2 kb from the TSSs (*** P < 0.001, ** P < 0.01 and * P < 0.05). (b) Hypermethylation prone promoter regions are evolutionarily
conserved. Shown are graphs of the level of conservation found in 500bp intervals around hypermethylation prone and resistant TSSs.
Conservation was assessed through two different methods: one measuring the rate of basepair substitutions between species, ‘bp Changes’ [46],
and the other measuring the rate of insertions and deletions between species, ‘Indel. Pur.’ [47]. The significance of observed differences between
hypermethylation-prone and -resistant genes was assessed using a Wilcoxon rank sum test for the scores ± 2 kb from the TSSs.
(c) Hypermethylation prone genes are found adjacent to lincRNAs. Shown is a chart of the percent of hypermethylation-prone and -resistant
genes found neighboring a lincRNA [49]. The significance of differences between the gene sets was assessed using Fisher’s exact tests. lincRNA,
long intergenic non-coding RNAs; LTR, long terminal repeat; TSSs, transcriptional start sites.
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hypermethylation prone genes defined from either
MBD-seq or whole-genome bisulfite sequencing profil-
ing of colorectal tumors [37-39] (See Additional file 2,
Figure S3B) suggesting that this property was not an
artifact of data generated from Illumina Infinium arrays.
Recently, long intergenic non-coding RNAs (lincR-
NAs) have been proposed to play a cis regulatory role at
some tissue specific genes [48]. Their presence is there-
fore a further surrogate of regulatory complexity at
nearby genes, so we asked whether lincRNAs were
enriched at hypermethylation prone genes. As predicted,
we found that hypermethylation prone genes were signifi-
cantly enriched in neighboring lincRNAs defined in a
recent comprehensive analysis of human tissues when
compared to hypermethylation resistant genes (Figure 3d)
[49]. Thus, hypermethylation prone genes are normally
expressed in a tissue-specific manner and the vicinity of
their promoters is depleted of repeats and is evolutionarily
conserved compared to hypermethylation resistant genes.
We propose that these characteristics result from an evo-
lutionary need to preserve regulatory elements required
for the proper regulation of genes prone to hypermethyla-
tion in cancer during normal development.
Variation in hypermethylation patterns in tumors is
determined by gene expression patterns in the tissue
of origin
Although repeat occupancy and conservation differ
between hypermethylation-prone and -resistant genes,
these factors displayed overlapping distributions for the
two gene sets (See Additional file 2, Figure S3C and D).
For example, some hypermethylation prone genes comple-
tely lacked SINE elements in the vicinity of their TSSs but
other hypermethylation prone genes were found with
more SINE elements than the average hypermethylation
resistant gene (See Additional file 2, Figure S3C). Also,
repeat occupancy and evolutionary conservation are invar-
iant between different tissues and so do not explain the
variable susceptibility of some genes to hypermethylation
between cancers of different tissues (Figure 1a). Therefore,
there must be other determinants of a gene’s susceptibility
to hypermethylation in a particular cancer.
To uncover such determinants, we considered genes
with variable methylation between tumors (VM genes, 446
hypermethylation prone genes defined as being never
hypermethylated in at least one cancer type, see Additional
file 3 and Figure 1a, tick marks). For comparison, we also
defined a set of 220 consistently methylated (CM) genes
that are methylated in all 7 cancer types (≥5% of samples
of each tumor type, see Additional file 4). Both VM and
CM genes were expressed in a more tissue specific fashion,
depleted in repetitive elements and evolutionarily con-
served compared to hypermethylation resistant genes
(Figure 4a andAdditional file 2, Figure S4A and B). How-
ever, the expression of CM genes in normal tissues was
significantly more tissue-specific than VM genes (Figure
4a). This suggests an inverse relationship between a gene’s
breadth of expression in normal tissues and the number of
cancers in which it becomes hypermethylated; that is,
genes that are expressed in fewer tissues become hyper-
methylated in more tumor types. In support of this rela-
tionship, we observed a significant correlation between a
gene’s specificity of expression in normal tissues and the
number of tumors in which it was frequently hypermethy-
lated (See Additional file 2, Figure S4C).
We have previously demonstrated that a gene’s expression
status in normal cells is linked to its susceptibility to
hypermethylation in breast cancer by showing that genes
repressed in a lineage-specific fashion in the normal breast
are prone to hypermethylation in different subtypes of
breast cancer cell lines and tumors [18]. We, therefore,
examined whether gene expression patterns in normal tis-
sues might explain the differential susceptibility to hyper-
methylation for VM genes in cancer. Examination of the
list of VM genes along with their susceptibility suggested
this might be the case. For example, PAX6 is prone to
hypermethylation in cancer but not in glioblastomas (See
Additional file 3). The gene is vital for the normal develop-
ment of the brain and its expression persists into adult-
hood [50]. Similarly, GFI1 is prone to hypermethylation in
cancer but not in AML and is vital for normal hematopoi-
esis; mice and humans lacking functional GFI1 are neutro-
penic suggesting that GFI1 functions in myleopoiesis and
is expressed in the cells from which AMLs originate
[51,52].
We tested if normal expression patterns determined
hypermethylation susceptibility by considering VM genes
with differential susceptibility in individual cancer types.
VM genes that were frequently hypermethylated in breast
tumors (67 genes) were repressed in the cells of origin of
most breast tumors, luminal epithelial cells [53], as com-
pared to normal breast stromal cells (Figure 4b, GEO:
GSE16997). Conversely, VM genes that were never hyper-
methylated in breast tumors were active in luminal epithe-
lial cells (Figure 4b, 86 genes). Similarly, VM genes
resistant to hypermethylation in colorectal tumors, glio-
blastomas and lung tumors were significantly more active
in the corresponding normal tissue than VM genes prone
to hypermethylation in the same tumor type (Figure 4c,
SRA:SRA008403), and genes that were hypermethylated
in colorectal tumors, as defined by MDB-seq or whole-
genome bisulfite sequencing, were also significantly less
active than those that did not become hypermethylated
(See Additional file 2, Figure S4D). Furthermore, expres-
sion status in normal tissues was predictive of aberrant
hypermethylation in cancer as genes which were repressed
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in normal colon compared to normal liver were signifi-
cantly more likely to be hypermethylated in colorectal
tumors than genes that are active in normal colon but
repressed in the normal liver (Figure 4d, one-sided Wil-
coxon rank sum test P = 1.6 × 10-7, GEO:GSE13471). We
have previously shown a similar preference for genes spe-
cifically repressed in luminal epithelial cells to be hyper-
methylated in breast tumors [18]. Together these analyses
suggest that variability in promoter hypermethylation pat-
terns between cancer types results from the variability in
Figure 4 Expression patterns in normal tissues explain differential susceptibility to hypermethylation in cancer. (a) Consistently
hypermethylated genes are more tissue specific than variably hypermethylated genes. Shown are histograms of tissue-specificity scores (as
Figure 2b) observed at hypermethylation prone genes that were consistently or variably methylated in different tumor types. Differences
between gene sets were tested using Wilcoxon rank sum tests (*** P < 0.001, ** P < 0.01 and * P < 0.05). (b) Variably hypermethylated genes
with differential susceptibility in breast cancer are differentially expressed in normal breast tissue. Shown are boxplots of the relative level of
expression in different cells from normal breast found at VM genes that are either frequently or never hypermethylated in breast tumors [85].
Differences between cellular fractions were tested using Wilcoxon rank sum tests. Lum = luminal epithelial cells, Lum Pro = luminal progenitor
cells, Bas = basal myoepithelial cells, Stroma = breast stromal cells. (c) Variably hypermethylated genes that are prone to hypermethylation in
tumors are repressed in the corresponding normal tissue. Shown are boxplots of the expression levels measured for VM genes with different
susceptibility in individual tumor types in the corresponding normal tissues. Res = never hypermethylated in tumors, Prone = frequently
hypermethylated in tumors. Differences between gene groups were tested using Wilcoxon rank sum tests. (d) Repressed genes are more prone
to hypermethylation than active genes in colorectal cancer. Shown are heatmaps of the methylation levels of CGI promoter genes that are
unmethylated in normal colon tissue and are either activated (left) or repressed (right) in normal colon as compared to normal liver. The 356
repressed genes are methylated to a significantly higher level than the 1,465 active genes (one-sided Wilcoxon rank sum test P = 1.6x10-7). CGI,
CpG island; VM, variably methylated.
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gene expression patterns in normal tissues, and that genes
that become hypermethylated in cancer are repressed in
the pre-cancerous tissue of origin.
Discussion
The aberrant hypermethylation of CGI promoters is of
interest because it correlates with gene silencing and can
occur at tumor suppressor genes [54]. Here, we present the
first comprehensive analysis of CGI promoter hypermethy-
lation in multiple cancer types and show that the genes
that are hypermethylated are already repressed in the nor-
mal tissues that give rise to these tumors (Figure 5a). The
potential for a gene to act as a tumor suppressor is depen-
dent on its activity in a particular cellular context. Our
study, therefore, demonstrates that the major contribution
of general CGI promoter hypermethylation to cancer can-
not be the silencing of tumor suppressor genes because it
affects genes that are already repressed in pre-cancerous
tissue.
During normal development, DNA methylation accu-
mulates at loci that are already repressed and may facili-
tate stable transcriptional repression rather than directly
cause silencing [55]. We have previously demonstrated
that breast cancer cell lines and tumors of different
lineages preferentially hypermethylate genes that are
already silent in their equivalent normal cells [18]. Our
current study extends this to tumors arising in different
tissues and suggests that the hypermethylation of
repressed genes represents a universal principle across all
cancers. Other studies of individual genes also support
this conclusion, for example, RUNX3 is frequently hyper-
methylated in gastric cancers but is never expressed in
normal gastric epithelia [20]. Therefore, CGI promoter
hypermethylation in cancer shares features with pro-
cesses that occur in normal cells and does not necessarily
represent a de novo aberrant mechanism.
Our analyses show that this model applies to the major-
ity of hypermethylated genes found in tumors, but it has
been proposed that within each tumor a few ‘driver’ genes
are directly repressed by hypermethylation [54]. Under
this scenario, the hypermethylation of repressed genes
could be a ‘passenger’ event and is a surrogate of epige-
netic dysregulation. An analogous model is proposed for
genetic mutations in cancer [56,57]. Known tumor sup-
pressor genes are hypermethylated in the tumors we ana-
lyzed but methylation of these genes generally occurs
much more rarely than the hypermethylation of repressed
genes, suggesting that a driver/passenger model may in
fact apply (See Additional file 2, Table S1). For example,
the hypermethylation of BRCA1 only occurs in 12% of
ovarian cancers and 2% of breast cancers. We find that
APC is hypermethylated more frequently (for example, in
33% of colorectal cancers) but it has multiple TSSs and a
promoter that is repressed in normal gastric tissue has
been shown to be the site of hypermethylation in gastric
cancers [19]. Therefore, the significance of frequent APC
hypermethylation depends on whether it occurs at the
major promoter in these tissues. It is unclear whether the
hypermethylation of these potential driver genes occurs as
a by-product of the process that results in the hyper-
methylation of repressed genes or by an alternative
mechanism (for example, the direct selection of epimuta-
tions). It is known that MLH1 is frequently hypermethy-
lated in colorectal tumors that possess a CIMP phenotype
[5]. However, if methylator phenotypes do generally con-
tribute to the repression of driver genes, we would expect
tumors with higher levels of promoter CGI hypermethyla-
tion to demonstrate more aggressive clinical behavior
because they would be statistically more likely to have
inactivated more tumor suppressor genes. Tumors with
methylator phenotypes in colorectal cancer, breast cancer
and glioblastoma correlate with better clinical prognosis
[7,8,58].
Our results confirm a previous observation that the
promoters of genes prone to aberrant hypermethylation
in cancer are depleted of repetitive elements [42]. How-
ever, we suggest that this occurs due to an evolutionary
Figure 5 Model: Variation in tumor hypermethylation profiles
reflects gene expression in normal tissue. (a) Genes repressed in
a tissue-specific manner are prone to hypermethylation in tumors
derived from that tissue. (b) Possible mechanisms that result in the
hypermethylation of repressed CGI promoters in cancer. CGI
promoter hypermethylation could result from either the loss of a
mechanism maintaining CGIs in a hypomethylated state (for
example,TET enzymes) or a gain of de novo methyltransferase
activity at the CGI (whether targeted by transcription factors or
through an increase in levels of the proteins in the cell). CGI, CpG
island.
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need to preserve the regulation of these genes in normal
development rather than as a direct protective effect of
repeats as was suggested [42]. Our conclusion that hyper-
methylation resistant genes are primarily housekeeping
genes is supported by another study that associated the
presence of motifs for general transcription factors with
resistance to hypermethylation in cancer [59]. The fea-
tures we associate with hypermethylation prone genes
overlap with those of genes regulated by Polycomb repres-
sive complexes. For example, the prototypical gene of this
class, HOX genes, are found in clusters that are devoid of
repetitive elements and are regulated by lincRNAs [60,61].
Previous studies have linked promoter hypermethylation
in cancer to Polycomb and the overlap between Poly-
comb-marked genes in embryonic stem (ES) cells and
genes hypermethylated in cancer has been noted [30].
However, the profile of Polycomb marks in a single cell
type is constant and does not account for the variability in
hypermethylated genes between cancers of different tis-
sues. Furthermore, although sets of hypermethylated genes
are statistically enriched in these Polycomb-marked genes,
only 30% to 60% of hypermethylated genes carry these
marks in ES cells [5,18]. Polycomb-marked genes in ES
cells carry bivalent histone modifications and are differen-
tially activated or repressed in alternative cell lineages as
differentiation proceeds [62,63]. It is therefore possible
that these genes are prone to methylation because they
can be repressed in a tissue-specific fashion rather than
because of their association with Polycomb in ES cells.
We find that the aberrant hypermethylation of repressed
genes occurs in all cancer types analyzed implying that a
common mechanism might be responsible for promoter
hypermethylation in all cancers. Although the exact
mechanism remains unknown, our results mean that pro-
posed mechanisms must account for the specificity of
hypermethylation for repressed genes (Figure 5b). For
example, if aberrant hypermethylation results from the
loss of an activity protecting CGIs from hypermethylation
in normal cells [3] then the specificity of hypermethylation
for repressed genes implies that different factors are
responsible for maintaining hypomethylation at repressed
and active CGIs or that hypomethylation is maintained at
active CGIs via multiple redundant mechanisms that are
not all present at the CGI promoters of repressed genes.
TET (ten-eleven translocation) hydroxylase enzymes may
be capable of mediating this protective activity through
their proposed role in DNA demethylation [64] and inhibi-
tion of their enzymatic activity in cancer correlates with
the hypermethylation of CGIs [65]. Aberrant hypermethy-
lation could also result from the recruitment of DNA
methyltransferases (DNMTs) by transcription factors
[66,67]. However, transcription factors also activate genes
and it remains to be demonstrated how these interactions
might result in the specific hypermethylation of repressed
genes. Over-expression of DNMT3B promotes tumorigen-
esis in a mouse model of colorectal cancer and is asso-
ciated with the hypermethylation of specific genes [68].
Higher DNMT3B levels have also been associated with the
CIMP phenotype in human colorectal tumors [69,70].
One of these studies also determined the stage in tumori-
genesis at which different genes became hypermethylated
showing that the repressed gene RUNX3 was the earliest
CGI promoter to show significant change [20,69], suggest-
ing that differences in the expression of DNMTs could be
linked to the hypermethylation of repressed genes.
Here we have shown that differences exist in the aber-
rant hypermethylation profiles of cancers arising in differ-
ent tissue contexts. However, our results also make it clear
that there is heterogeneity in the methylation profiles
within particular types of cancer (Figure 1a). It is unclear
how this heterogeneity arises but some mutations may
play a direct role in its generation, for example, those that
inhibit TET enzyme activity [8,65]. Colorectal cancer has
previously been split into at least three groups based on
methylation profiles: non-CIMP tumors, CIMP-high
tumors associated with BRAF mutations and CIMP-low
mutations associated with KRAS mutations [5,71]. Inter-
estingly, a recent study suggested that CIMP-low tumors
hypermethylate a subset of the genes hypermethylated in
CIMP-high tumors rather than distinct sets of genes [5].
Our own results might also suggest that variation between
cancers in a given tissue can manifest itself as variable
levels of methylation at methylation prone genes rather
than the hypermethylation of alternative gene sets (see
Figure 1a). We have previously shown that differences in
the hypermethylation profiles of breast cancer subtypes of
putatively different cells of origin can arise because of dif-
ferences in gene expression in normal cell populations
[18]. Taken together, these results suggest that the hyper-
methylation of genes that are repressed in the normal cells
of origin can account for the heterogeneity of tumor
methylation profiles and variation in aberrant hypermethy-
lation arises due to variations in the cells of origin or other
factors, such as mutations, that influence the strength of
the repressed gene methylator phenotype.
Recently, hydroxymethylated cytosine (hmC) has been
re-discovered as a DNA modification present at significant
levels in mammalian cells [72]. The Illumina arrays that
were used to generate most of the datasets we have ana-
lyzed are unable to distinguish methylated cytosine (mC)
from hmC [73] and the results we present may relate to
hmC rather than mC marked promoters in cancer. How-
ever, we have confirmed that these results equally apply in
additional datasets derived by MBD pull-down, which is
specific for 5mC (See Additional file 2, Figures S2D, S3B
and S4D). In addition, hmC appears to be generally
depleted in cancer [74-76]. It is likely, therefore, that
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repressed genes are prone to hypermethylation rather than
hyperhydroxymethylation.
Conclusions
In summary, our results argue that the bulk of aberrant
promoter hypermethylation in cancer occurs predomi-
nantly at genes that are repressed in pre-cancerous tissue
and therefore does not directly contribute to tumor pro-
gression by silencing tumor suppressor genes. This epige-
netic alteration is common to all the cancer types we
have analyzed implying that a common mechanism is
responsible for promoter hypermethylation at repressed
genes in all cancers. Future research in this field should,
therefore, focus on confirming whether aberrant hyper-
methylation does directly suppress rare driver genes and
if the mechanism responsible for driver gene suppression
is the same as that acting at repressed genes. Finally, we
would suggest that researchers must exercise caution in
assigning a tumor suppressor status to a gene based on
its propensity to become hypermethylated in cancer.
Materials and methods
Statistical analyses
All statistical analyses were performed using the R sta-
tistical software (version 2.12.1) [77]. Additional
packages used are mentioned under the appropriate
section.
Data sources
Gene expression and methylation data used in this study
were taken from previously published studies. The
sources of the data are indicated in Table 1 and the
number of samples in each dataset in Table 2.
Genome annotation
In order to apply a consistent annotation to the data
used in this study, all data were re-annotated to
Ensembl 54 gene IDs (NCBI36). CpG probes from the
Illumina Infinium arrays were mapped to the closest
Ensembl gene based on TSS location using custom Perl
and R scripts. CpGs that ambiguously mapped to more
than one gene ID were removed from the analysis. CGI
locations were taken from those biologically defined in a
recent study [38]. Similarly, expression data were
mapped as previously described for Illumina expression
arrays [18] or using publically available re-annotations
for Affymetrix expression arrays [78]. RNAseq data were
mapped to Ensembl gene IDs as described below. lincR-
NAs were mapped to neighboring Ensembl gene IDs as
described below.
Processing of methylation data
For data originating from Infinium methylation arrays,
beta values were used as a measure of the methylation
level at a given CpG probe (derived from the intensity
Table 1 Sources of methylation and expression data.
Tissue Type Reference Data Source Type
Breast Tumor [23] GEO (GSE31979) Methylation (Inf 27k)
Colorectal Tumor [5] GEO (GSE25062) Methylation (Inf 27k)
Prostate Tumor [24] GEO (GSE26126) Methylation (Inf 27k)
Glioblastoma [8] TCGA [22] Methylation (Inf 27k)
Lung Tumors [22] TCGA [22] Methylation (Inf 27k)
AML [22] TCGA [22] Methylation (Inf 27k)
Ovarian Tumors [25] TCGA [22] Methylation (Inf 27k)
Normal Tissues [18] GEO (GSE26990) Methylation (Inf 27k)
Normal Tissues [81] GEO (GSE30090) Methylation (Inf 27k)
Colorectal Tumors [38] Publication Supplementary Dataset S1 [40] Methylation (MBD-seq)
Colorectal Tumors [39] SRA (SRA029584) Methylation (MBD-seq)
Colorectal Tumor [37] Author’s Website [41] Methylation (WG bis-seq)
Breast Tumors [7] GEO (GSE26349) Methylation (Inf 27k)
Breast Tumors [18] GEO (GSE26990) Methylation (Inf 27k)
Breast Tumors [28] Author’s Website [82] Methylation (Inf 27k)
Normal Tissues [36] GEO (GSE2361) Expression (Affy 133A)
Normal Tissues [34] SRA (SRA008403) Expression (RNA-seq)
Normal Breast Tissue Cell Fractions [85] GEO (GSE16997) Expression (Ill v3)
Normal Colon and Liver [89] GEO (GSE13471) Expression (Affy 133plus2)
Details of data sources used in each study. The tissue type found in each dataset, the study this data were taken from, the data type and the source of the
original data used are indicated. GEO and SRA accession numbers are included in the table along with links to data from other sources. Inf 27k, Illumina Infinium
HumanMethylation27 BeadChip array; MBD-seq, Methyl Binding Domain pull-down followed by sequencing; WG bis-seq, whole genome bisulfite sequencing; Affy
133A, Affymetrix U133A genechip; Affy 133plus2, Affymetrix U133plus2 genechip; Ill v3,Illumina WG6 V3.0 human beadchips. Data from Noushmehr et al. 2011
(Glioblastoma methylation)[8] and TCGA 2011 (Ovarian tumor methylation)[25] were limited to IDs identified in these publications when downloaded from the
TCGA website[22]. Methylation data from lung tumors and AML were downloaded from the TCGA website on 19 October 2011. AML, acute myeloid leukemia.
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of the methylated, Imeth, and unmethylated, Iunmeth, allele
probes: Imeth /(Imeth + Iunmeth) ). We have previously
shown that these are a reliable estimate of the level of
methylation at a locus [18]. These data were then fil-
tered to remove unreliable values based on the detection
P-value from the Infinium arrays (threshold 0.01).
Methylation data originating from other techniques
(MDB-seq or whole-genome bisulfite sequencing) were
either downloaded as processed data provided by the
authors [37,38] or processed from raw sequencing files
[39]. We first downloaded raw sequencing data from the
SRA [35]. We then aligned these reads to the genome
using Bowtie (version 0.12.7) [79] and the BEDtools
(version 2.12.0) coverageBED tool to quantify the num-
ber of reads at each CGI [80]. The read counts of CGIs
were then normalized for CGI length and the total
number of reads per sample to obtain a reads per kb
per million mapped reads (RPKM) value for each CGI
and the mean value taken from replicates of individual
samples.
Definition of hypermethylation-prone and -resistant
genes
Hypermethylation-prone and -resistant genes were
defined from Illumina infinium array data using beta
value cutoffs (roughly equating to percent methylation
divided by 100). Previously, we have shown that probes
with beta values <0.3 represent unmethylated areas of the
genome [18] and we therefore defined unmethylated
probes on this basis. In cell lines, we have previously
shown that probes with beta >0.7 represent genomic loci
that are fully methylated [18]. However, in a preliminary
analysis, we found that in the breast tumor samples used
here, probes that had beta values >0.7 were also all
methylated in normal breast tissue (data not shown).
Probes that were aberrantly hypermethylated in these
tumors had lower beta values because of the mix of can-
cerous and normal tissue in the samples analyzed. In this
study, we therefore set a beta value threshold of >0.3 to
define methylated probes. We only considered probes
that were located within a CGI and within 200bp of a
TSS that were unmethylated in all available normal sam-
ples from that tissue when defining gene sets (the ‘all’
genes control set for each tumor type). Frequently hyper-
methylated genes for each cancer were defined as genes
satisfying these criteria that were methylated in at least
20% of tumor samples. Similarly, hypermethylation resis-
tant genes satisfied these criteria but were not found to
be methylated in any of the tumors. Genes present in
both lists were then excluded from the analysis as being
of ambiguous status to control for the presence of multi-
ple probes at some genes.
To ensure that the method of gene selection did not
bias our results, we also carried out analyses in which
parameters were varied (See Additional file 2, Figure S2B
and data not shown). We considered two major varia-
tions: we varied the threshold used to define aberrantly
methylated genes and we varied the threshold required to
call genes frequently aberrantly hypermethylated. In the
first case, aberrantly hypermethylated genes were defined
as those for which no probes had beta >0.3 in normal tis-
sue and for which their mean beta value was >0.5 in at
least 20% of cancers of a given type. In the second case,
we varied the percent of samples required for a gene to
be defined as frequently hypermethylated from 10% to
50%.
Two of the datasets used did not contain normal sam-
ples to define probes’ normal tissue methylation status.
Table 2 Dataset sample numbers for cancer methylation data.
Tissue Type Number of Cancer Samples Number of Normal Samples Technology
Fackler Breast Tumors 103 21 Infinium 27k
Fang Breast Tumors 39 2 Infinium 27k
Sproul Breast Tumors 34 2 Infinium 27k
Van der Auwera Breast Tumors 62 10 Infinium 27k
Colorectal Tumors 125 29 Infinium 27k
Illingworth Col. Tum. 5 5 MDB-seq
Xu Col. Tum. 6 3 MDB-seq
Berman Col. Tum. 1 1 WG bis-seq
Prostate Tumors 95 86 Infinium 27k
Glioblastomas 88 2 Infinium 27k
Lung Tumors 66 24 Infinium 27k
AMLs 188 8 Infinium 27k
Ovarian Tumors 484 8 Infinium 27k
Details of the number of methylation profiles analyzed for each cancer type. The cancer type, the number of cancer and normal samples analyzed and the
technology used to generate the methylation profiles in each case are shown. AMLs, acute myeloid leukemias; Col. Tum, colorectal tumors; Infinium 27k, Illumina
infinium Infinium HumanMethylation27 BeadChip array; MBD-seq, Methyl Binding Domain pull-down followed by sequencing; WG bis-seq, whole genome
bisulfite sequencing.
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In these cases, we made use of other datasets. For glio-
blastoma we used the fetal and adult brain samples
from Sproul et al. [18]. For AML we used the whole
blood, neutrophils, B-cells, CD4 and CD8 T-cells, nat-
ural killer cells and CD34+ hematopoeitic stem cells
samples from Calvanese et al. [81]. We then defined the
1,009 hypermethylation prone genes from those being
frequently hypermethylated in at least 1 of the 7 can-
cers, and the 2,123 hypermethylation resistant genes as
those that were never methylated in any of the tumors
analyzed. Consistently and variably prone genes (CM
and VM, respectively) were defined as hypermethylation
prone genes that were methylated in at least 5% of
tumors of each type or never methylated in at least one
tumor type, respectively.
To validate the reproducibility of our method of defining
hypermethylation prone genes, we compared our list of
genes frequently hypermethylated in breast tumors to a
second list defined by the cross-comparison of three inde-
pendent studies [7,18,28]. Data from these studies were
either downloaded from GEO or from the author’s website
(GEO: GSE26349 and GSE26990) [82]. Frequently hyper-
methylated genes were defined as above but only genes
that were frequently hypermethylated in all three datasets
were included in the analysis.
To define frequently hypermethylated and resistant
genes from the Illingworth et al. MBD-seq data, we first
generated lists of CGIs that were unmethylated in all of
the normal colon samples [38]. We then defined those
CGIs that had higher levels of methylation in at least two
of the tumor samples when compared to their matched
normal samples as frequently hypermethylated CGIs.
Resistant CGIs were defined as those that did not show
higher levels of methylation in any of the tumors com-
pared to their matched normal tissues. CGIs were assigned
to genes if their transcription start site was present in the
CGI. Genes present in both frequent and resistant lists
were also removed because their status was ambiguous.
To define genes which were hypermethylated in colorec-
tal tumors from the Xu et al. MDB-seq data [39], we used
one-sided Wilcoxon rank sum tests to find CGIs with sig-
nificantly more reads in tumor samples than normal sam-
ples (P < 0.05). CGIs were assigned to genes if their TSS
was present in the CGI. Using this methodology, we were
unable to define a set of hypermethylation resistant genes.
We defined genes prone to and resistant to hyper-
methylation from the Berman et al. whole- genome bisul-
fite sequencing data [37] as genes with CGI TSSs which
were located in regions defined as methylation-prone or
-resistant in that study. These regions were downloaded
from the author’s website. Genes which were defined as
both methylation-prone and -resistant were excluded as
being of ambiguous status.
Processing of expression data
To process RNA-seq data, raw sequence data for nine
human tissues [34] were downloaded from GEO and con-
verted to FASTQ format using the SRA Toolkit (version
2.1.7). Several technical replicates were available for each
tissue. However, we randomly chose a single replicate in
each case for simplicity and because different tissues had
different numbers of replicates in this dataset. We exam-
ined each sample for per-base and per-read quality and
over-represented kmers using the FastQC software (ver-
sion 0.9.4) [83]. Reads were mapped simultaneously to the
human genome (NCBI version 36/hg18) and a library con-
taining the sequences of all possible exon splice junctions
(Ensembl 54 exons) created using RSEQtools [84]. Reads
were mapped using Bowtie (version 0.12.7) [79] allowing
for a maximum of two mismatched bases and reporting
the single best alignment for each read. RPKM values
were computed for each ENSEMBL gene using reads map-
ping to exons and junctions of its longest transcript.
Processed Illumina gene expression data were down-
loaded from GEO and summarized to individual Ensembl
IDs by taking the mean value of all probes mapped to
that gene [85]. Reported probe detection values were
used to remove genes from the analysis for which all
probes had a value >0.05 in all samples. Affymetrix
expression data were summarized using the RMA algo-
rithm from the Bioconducter affy package and an
updated annotation [78]. Detection calls were also gener-
ated using the MAS5 algorithm in the Bioconducter affy
package.
To define CGI genes that were differentially expressed
between normal colon and normal liver, we assayed for
differential expression in processed expression microar-
ray data using t-tests and Benjamini-Hochberg correction
for multiple testing (assuming unequal variance and with
a false discovery rate (FDR) of 5%). We then refined
these lists to only those that had CGI promoters and had
probes on the Infinium array within 200bp of their TSS
that were unmethylated in normal colon (1,456 colon
active and 356 colon repressed genes) before comparing
methylation levels in colorectal tumors between these
groups.
Analysis of GO-terms
To analyze functional terms, Ensembl Biomart was used
to map gene identifiers to GO biological process terms
(Ensembl 54). Enrichment of specific terms in each gene
list was then assessed using Fisher’s exact test as com-
pared to all genes present on the Infinium array. Terms
that were associated with less than 10 genes on the Infi-
nium arrays were excluded from the analysis. Data were
presented as change in the percent of genes in each set as
compared to the control.
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Definition of tissue specificity of gene expression
The specificity of a gene’s expression pattern in normal
tissues was measured using a method based on informa-
tion theory [33]. A low score indicates that a gene is uni-
formly expressed and a high score indicates that it is
expressed specifically in one tissue. For plotting, we cal-
culated the specificity for all genes and then split them
into five equally sized groups of increasing specificity.
We first removed any genes from the analysis that were
potentially unexpressed in all assayed samples. For
microarray expression data this was done using Affyme-
trix MAS5 detection calls by defining genes that were
‘absent’ in all samples as being unexpressed in all tissues.
For RNA-seq, genes unexpressed in all tissues were
defined as those that had RPKM values of 0 in all tissues.
The specificity of individual gene sets was examined by
plotting their distribution across the five specificity
groups or by plotting the scores themselves. To test sig-
nificance, the specificity scores of gene sets were com-
pared using Wilcoxon rank sum tests.
Definition of genes mutated in breast cancer
Genes reported as mutated in breast cancer were defined
using the Catalogue of Somatic Mutations in Cancer
(COSMIC, [86]) database [87]. Reports of genes mutated
or not mutated in breast cancer samples were down-
loaded from COSMIC biomart (version 52B) and used to
generate two lists of genes: those mutated in at least two
samples and those not mutated in any. Lists were further
limited to only those genes with CGI promoters (341
mutated and 10,117 non-mutated genes). The control set
for this analysis was all CGI promoter genes reported as
analyzed in breast cancer by COSMIC (11,022 genes).
Analysis of repetitive elements at promoters
To define the density of repetitive elements around TSSs,
repetitive element positions were downloaded from the
Repeat Masker track of the University of California, Santa
Cruz (UCSC) genome browser (hg18) [88]. Custom R
scripts were then used to determine whether a repeat of a
given class was present in a particular genomic interval.
Repeats were defined as being present if they overlapped
this interval. Genes were analyzed with respect to their
TSS in non-overlapping 1 kb windows upstream and
downstream of the TSS (with respect to the direction of
transcription). To compare gene sets we plotted the fre-
quency of repeats found at each window within that set.
Differences between sets were tested using Fisher’s exact
tests based upon the density of repeats within a window ±
2 kb from TSSs.
Analysis of evolutionary conservation at promoters
We defined the level of conservation around gene pro-
moters using two different measurements. The first was
based upon the measurement of base substitutions
between 17 vertebrate species [46]. To define this score,
the ‘aggregate’ tool from the Galaxy suite of bioinfor-
matic tools was used to generate mean Phastcons (con-
servation) scores in 500bp windows surrounding each
TSS (using the Phastcons 17-vertebrate alignments from
genome build hg18). The second score was defined
using data on sequences that showed a significant deple-
tion of short insertions and deletions in comparisons of
multiple species [47]. We downloaded the locations of
these sequences from the UCSC browser (hg18) [88]
and then used the coverageBed tool from the BEDtools
suite of bioinformatics tools [80] to calculate the percent
of a given genomic interval occupied by these insertion
and deletion purified sequences. Genes were analyzed
with respect to their TSS in non-overlapping 500bp win-
dows upstream and downstream of the TSS (with
respect to the direction of transcription) by deriving
mean scores for genes in the set. The significance of dif-
ferences between gene sets was tested using the scores
calculated for the window -2 to +2 kb from the TSS and
Wilcoxon rank sum tests.
Analysis of genes neighboring lincRNAs
We used a recent survey of lincRNAs in the human
genome to define genes that had a neighboring lincRNA
[49]. The nearest genic neighbor of each lincRNA was
defined from that study’s supplementary data and the
given Refseq IDs mapped to Ensembl gene IDs. Gene
sets were compared by examining the proportion of
genes that had a lincRNA as their closest neighbor and
significance was tested using Fisher’s exact tests.
Additional material
Additional file 1: 1,009 hypermethylation prone genes. Excel file
containing details of the 1,009 hypermethylation prone genes in the
7 cancer types.
Additional file 2: Supplementary data. PDF file containing four
supplementary figures, one table and their legends.
Additional file 3: 446 variably methylated genes. Excel file containing
details of the 446 variably hypermethylated genes along with their
susceptibility in the different cancer types.
Additional file 4: 220 consistently methylated genes. Excel file
containing details of the 220 consistently hypermethylated genes in the
7 different types of cancer.
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